Latest news with #Biotronik
Associated Press
03-05-2025
- Business
- Associated Press
Teleflex Incorporated Announcement: If You Have Suffered Losses in Teleflex Incorporated (NYSE: TFX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Teleflex Incorporated (NYSE: TFX) resulting from allegations that Teleflex may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Teleflex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. WHAT IS THIS ABOUT: On February 27, 2025, during market hours, Fierce Biotech published an article entitled 'Teleflex plays musical chairs, plans company split amid €760M Biotronik cardiovascular deal.' The article stated that 'Teleflex has announced a plan to split its business into two separate independent companies—and it's setting up one of its future scions with a new portfolio of cardiovascular device assets, set to be acquired from Biotronik.' On this news, Teleflex stock fell 21.6% on February 27, 2025. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
Malaysian Reserve
02-05-2025
- Business
- Malaysian Reserve
Teleflex Investor News: Rosen Law Firm Encourages Teleflex Incorporated Investors to Inquire About Securities Class Action Investigation
NEW YORK, May 1, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Teleflex Incorporated (NYSE: TFX) resulting from allegations that Teleflex may have issued materially misleading business information to the investing public. So What: If you purchased Teleflex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@ for information on the class action. What is this about: On February 27, 2025, during market hours, Fierce Biotech published an article entitled 'Teleflex plays musical chairs, plans company split amid €760M Biotronik cardiovascular deal.' The article stated that 'Teleflex has announced a plan to split its business into two separate independent companies—and it's setting up one of its future scions with a new portfolio of cardiovascular device assets, set to be acquired from Biotronik.' On this news, Teleflex stock fell 21.6% on February 27, 2025. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Kim, Rosen Law Firm, P.A.275 Madison Avenue, 40th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827case@
Business Wire
29-04-2025
- Business
- Business Wire
Rosen Law Firm Encourages Teleflex Incorporated Investors to Inquire About Securities Class Action Investigation
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Teleflex Incorporated (NYSE: TFX) resulting from allegations that Teleflex may have issued materially misleading business information to the investing public. So What: If you purchased Teleflex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@ for information on the class action. What is this about: On February 27, 2025, during market hours, Fierce Biotech published an article entitled 'Teleflex plays musical chairs, plans company split amid €760M Biotronik cardiovascular deal.' The article stated that 'Teleflex has announced a plan to split its business into two separate independent companies—and it's setting up one of its future scions with a new portfolio of cardiovascular device assets, set to be acquired from Biotronik.' On this news, Teleflex stock fell 21.6% on February 27, 2025. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by Law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Attorney Advertising. Prior results do not guarantee a similar outcome.
Yahoo
11-04-2025
- Business
- Yahoo
Teleflex to close Minnesota facility, cut 101 employees
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Teleflex will close a manufacturing facility in Maple Grove, Minnesota, by next March and cut more than 100 employees as a result. The planned closure will affect an expected 101 positions, according to a Tuesday Worker Adjustment and Retraining Notification filing obtained by MedTech Dive. The Minnesota Star Tribune first reported the cuts. Most laboratory and manufacturing operations are expected to cease by June 30, with the layoffs occurring on July 1, according to the filing. Teleflex did not respond to a request for comment on why it was closing the Maple Grove facility. In February, Teleflex announced it would split into two separate, public entities. A new company would comprise Teleflex's urology, acute care and OEM businesses, while the remaining company would include the vascular access, interventional and surgical businesses. Simultaneously, Teleflex bought Biotronik's vascular intervention division. Teleflex aims to streamline manufacturing during the restructuring. The company aims to reduce the number of facilities from the combination of Biotronik and the remaining company from 19 facilities to seven, CEO Liam Kelly told investors in February. The Maple Grove site was used to make diagnostic and interventional catheters, according to the company's website. Teleflex's remaining company had pro forma revenue of $2.1 billion in 2024 with the Biotronik acquisition. Recommended Reading Teleflex to split in 2, buy Biotronik assets for $791M among slew of actions
Reuters
27-02-2025
- Business
- Reuters
Medical device maker Teleflex to split lower growth units
Feb 27 (Reuters) - Medical equipment maker Teleflex (TFX.N), opens new tab said on Thursday it would split into two companies, retaining three of its segments along with its recently acquired $800 million business, while separating its slower-growing divisions. Shares of the company were down 12% in premarket trade after it also forecast its adjusted profit below Wall Street estimates. After the split, Teleflex would focus on devices for bloodstream and heart procedures, along with medical imaging, while separating its urology, acute care and OEM units. The urology unit has been experiencing lower sales from its UroLift device for enlarged prostate treatment, while the OEM or the contract instrument manufacturing division recently lost a customer. A total of 12 out of 19 manufacturing facilities will be transferred to the new company. Teleflex also plans to boost the remaining business by buying Germany-based Biotronik's blood vessel device unit for about 760 million euros ($796.3 million) in cash. It said the separation will allow each company to simplify operations, streamline manufacturing, allocate resources more effectively and increase management focus. Liam Kelly will stay as Teleflex CEO, and the company intends to initiate an executive search for key management positions at the spun-off business shortly. Teleflex said it would distribute shares of the spun-off company to shareholders and expects the separation to be completed in mid-2026. Separately, the Wayne, Pennsylvania-based company expects adjusted per-share profit for 2025 in the range of $13.95 to $14.35, below analysts' average estimate of $15.23 as per data compiled by LSEG. The company also said its Chief Financial Officer Thomas Powell will retire, and be replaced by accounting chief John Deren. ($1 = 0.9544 euros) Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
